WallStSmart

InspireMD Inc (NSPR)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 232846% more annual revenue ($25.27B vs $10.85M). SYK leads profitability with a 13.2% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 59/100 (C).

NSPR

Hold

41

out of 100

Grade: D

Growth: 8.0Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: -5.09

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NSPRUndervalued (+47.1%)

Margin of Safety

+47.1%

Fair Value

$3.26

Current Price

$0.93

$2.33 discount

UndervaluedFair: $3.26Overvalued
SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NSPR3 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
122.2%10/10

Revenue surging 122.2% year-over-year

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

NSPR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$35.85M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NSPR

The strongest argument for NSPR centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 122.2% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : NSPR

The primary concerns for NSPR are EPS Growth, Market Cap, Profit Margin.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

NSPR profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

SYK carries more volatility with a beta of 0.81 — expect wider price swings.

NSPR is growing revenue faster at 122.2% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 41/100). NSPR offers better value entry with a 47.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InspireMD Inc

HEALTHCARE · MEDICAL DEVICES · USA

InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?